Kutub Mahmood, PhD, is PATH’s Scientific Director, at the Center for Vaccines Innovation and Access (CVIA). Currently, leading projects for polio vaccines development and scaleup for OPV, Sabin IPV (sIPV) and hexavalent vaccine, reference standards development for novel OPV and sIPV. His other projects at PATH includes work related to measlesrubella, influenza, RSV, Yellow fever, live rotavirus, and SARS-CoV2 with technologies including whole virion, inactivated, vectored, live attenuated, VLPs and subunit vaccines. He holds national and international patents on VLP technology for influenza and RSV vaccines and include publications in peer-reviewed journals. At PATH, his work includes generating international reference standard for Sabin IPV, universal reagents for IPV potency testing and providing strategic and scientific support to other projects including RSV, COVID-19, influenza vaccine.

Dr Mahmood is a seasoned leader with expertise in viral vaccines with over 30yrs experience in vaccine development. Before joining PATH, he was a key contributor to the development of FluMist, a live intranasal influenza vaccine, at Medimmune. At Novavax, he was the Executive Director, Biologicals Product Discovery, and worked on virus like particles for influenza, RSV viruses. While at Novavax, Dr. Mahmood played a pivotal role in entering into a collaborative partnership with Cadila Pharmaceuticals, India where he transitioned as Vice President, Vaccines and Biologics, overseeing the tech transfer of H5N1 VLP vaccine and product development in India.

Dr. Mahmood did his doctoral thesis on flaviviruses at National Institute of Virology, India and later pursued postdoctoral training at MIT, USA. He has been in vaccine industry for over two decades before joining PATH. He presently serves on several scientific panels advisory board for biotech
companies in Europe, for national and international vaccine meetings, and serves as scientific reviewer for leading scientific journals.